Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25456073 | 0.84 | MEN1 (0.42) | LPAR1ALDH1A1TRPV4GAAMEN1 | |
| SCHEMBL364796 | 0.84 | ADRA2A (0.45) | LPAR1ALDH1A1TRPV4GAATSHR | |
| SCHEMBL20868996 | 0.84 | LMNA (0.55) | LPAR1ALDH1A1TRPV4MEN1KMT2A | |
| SCHEMBL16951333 | 0.84 | LPAR1 (0.41) | LPAR1ALDH1A1TRPV4GAAMEN1 | |
| SCHEMBL1748248 | 0.84 | LMNA (0.55) | LPAR1ALDH1A1TRPV4MEN1KMT2A | |
| SCHEMBL1911429 | 0.83 | LPAR1 (0.50) | LPAR1GABRA1GABRB1ALDH1A1TRPV4 | |
| SCHEMBL11890403 | 0.82 | CSNK2A1 (0.43) | LPAR1RORCGABRA1GABRB1POLB | |
| SCHEMBL21136940 | 0.82 | MEN1 (0.45) | LPAR1ALDH1A1TRPV4MEN1KMT2A | |
| SCHEMBL11292735 | 0.81 | TTR (0.43) | LPAR1THRBRORCALDH1A1TRPV4 | |
| SCHEMBL11890402 | 0.80 | GAA (0.52) | GABRA1GABRB1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-11358940-B2 | K-Ras modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | disclosed |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-20070232648-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070043014-A1 | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | LPAR1 3363/4885THRB 1004/4885RORC 139/4885 |
| US-20070043014-A1 | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | S1PR3, S1PR1, S1PR5 | LPAR1 12/4885THRB 1248/4885RORC 323/4885 |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | GCGR, GLP1R, GPR119 | LPAR1 248/4885THRB 68/4885RORC 784/4885 |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, VHL | LPAR1 3320/4885THRB 1173/4885RORC 2285/4885 |
| US-11358940-B2 | K-Ras modulators | KRAS, HRAS, NRAS | LPAR1 1894/4885THRB 1832/4885RORC 1626/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | LPAR1 1971/4885THRB 1328/4885RORC 650/4885 |
| US-20070232648-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | NR3C1, NR3C2, MC2R | LPAR1 370/4885THRB 163/4885RORC 200/4885 |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | ACE2, ACE, TMPRSS2 | LPAR1 3923/4885THRB 4750/4885RORC 3544/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | LPAR1 3038/4885THRB 2871/4885RORC 452/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | LPAR1 3842/4885THRB 1175/4885RORC 3423/4885 |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | LPAR1 3540/4885THRB 2537/4885RORC 4082/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | LPAR1 2681/4885THRB 1349/4885RORC 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.